Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Business Wire
- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders.“At Sangamo, we believe that we can engineer zinc fin
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness Wire
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.MarketBeat
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
SGMO
Earnings
- 3/13/24 - Miss
SGMO
Sec Filings
- 4/5/24 - Form SC
- 4/3/24 - Form PRE
- 3/25/24 - Form 8-K
- SGMO's page on the SEC website